Limits...
Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA - PLoS Negl Trop Dis (2014)

View Article: PubMed Central - PubMed

Affiliation: Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Lymphatic filariasis (LF) is caused by filarial worms that live in the lymphatic system and commonly lead to lymphoedema, elephantiasis, and hydrocele... Global momentum to eliminate LF has developed over the past 15 years as a result not only of research demonstrating the value of single-dose treatment strategies and point-of-care diagnostic tools, but also of both the generous donations of medicines from the following committed pharmaceutical companies: GlaxoSmithKline (albendazole), Merck (ivermectin), and Eisai (diethylcarbamazine; DEC), and the essential financial support for programme implementation from the donor community... The MMDP component of the GPELF has the principal aim to provide access to basic recommended care, for every person with acute dermatolymphangioadenitis (ADLA), lymphedema, elephantiasis, or hydrocele in all areas where LF is endemic, thus alleviating suffering and promoting improvement in their quality of life... The recommended minimum package of care includes: treating episodes of ADLA/acute attacks among people with lymphoedema or elephantiasis, preventing both the debilitating and painful episodes of ADLA or acute attacks and the progression of lymphoedema or elephantiasis, enhancing access to hydrocele surgery, and providing antifilarial medicines through MDA or individual treatment to destroy any remaining worms and microfilariae... Intensive research efforts are focused on development and validation of new surveillance tools and strategies (such as the use of antibody assays to reflect exposure to infective larvae and xenomonitoring to confirm absence of parasites in the vectors), both to document the interruption of transmission of LF and to harmonize the process for verifying the elimination of LF with WHO verification processes for other diseases.

No MeSH data available.


Related in: MedlinePlus

Strategy of the global programme to eliminate lymphatic filariasis.Interrupting transmission through mass drug administration (MDA) and morbidity management and disability prevention (MMDP) in populations with LF [21].
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4263400&req=5

pntd-0003328-g001: Strategy of the global programme to eliminate lymphatic filariasis.Interrupting transmission through mass drug administration (MDA) and morbidity management and disability prevention (MMDP) in populations with LF [21].

Mentions: WHO launched the GPELF in 2000 in response to World Health Assembly resolution WHA50.29, which urged Member States to initiate activities to eliminate lymphatic filariasis (LF) as a public health problem, a goal subsequently targeted for 2020. This “global elimination of LF as a public health problem” has been operationally interpreted as the reduction in the prevalence of infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori in all endemic countries to target thresholds below which transmission of the infection cannot be sustained. These thresholds were earlier empirically observed to be less than 1.7% microfilaria (mf) prevalence for Bancroftian filariasis and less than 1.5% mf prevalence for Brugian filariasis [3], though current targets for GPELF are considerably more conservative [4]. In line with its first strategic plan [5], the GPELF has two principal aims: (i) to interrupt LF transmission, and (ii) to manage morbidity and prevent disability [6] (Fig. 1). In 2010, WHO published the GPELF's progress report from its first ten years and a new strategic plan outlining the approach and relevant milestones for its second ten years [2]. The report defines the strategic objective of each of GPELF's two aims as follows:


Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA - PLoS Negl Trop Dis (2014)

Strategy of the global programme to eliminate lymphatic filariasis.Interrupting transmission through mass drug administration (MDA) and morbidity management and disability prevention (MMDP) in populations with LF [21].
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4263400&req=5

pntd-0003328-g001: Strategy of the global programme to eliminate lymphatic filariasis.Interrupting transmission through mass drug administration (MDA) and morbidity management and disability prevention (MMDP) in populations with LF [21].
Mentions: WHO launched the GPELF in 2000 in response to World Health Assembly resolution WHA50.29, which urged Member States to initiate activities to eliminate lymphatic filariasis (LF) as a public health problem, a goal subsequently targeted for 2020. This “global elimination of LF as a public health problem” has been operationally interpreted as the reduction in the prevalence of infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori in all endemic countries to target thresholds below which transmission of the infection cannot be sustained. These thresholds were earlier empirically observed to be less than 1.7% microfilaria (mf) prevalence for Bancroftian filariasis and less than 1.5% mf prevalence for Brugian filariasis [3], though current targets for GPELF are considerably more conservative [4]. In line with its first strategic plan [5], the GPELF has two principal aims: (i) to interrupt LF transmission, and (ii) to manage morbidity and prevent disability [6] (Fig. 1). In 2010, WHO published the GPELF's progress report from its first ten years and a new strategic plan outlining the approach and relevant milestones for its second ten years [2]. The report defines the strategic objective of each of GPELF's two aims as follows:

View Article: PubMed Central - PubMed

Affiliation: Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Lymphatic filariasis (LF) is caused by filarial worms that live in the lymphatic system and commonly lead to lymphoedema, elephantiasis, and hydrocele... Global momentum to eliminate LF has developed over the past 15 years as a result not only of research demonstrating the value of single-dose treatment strategies and point-of-care diagnostic tools, but also of both the generous donations of medicines from the following committed pharmaceutical companies: GlaxoSmithKline (albendazole), Merck (ivermectin), and Eisai (diethylcarbamazine; DEC), and the essential financial support for programme implementation from the donor community... The MMDP component of the GPELF has the principal aim to provide access to basic recommended care, for every person with acute dermatolymphangioadenitis (ADLA), lymphedema, elephantiasis, or hydrocele in all areas where LF is endemic, thus alleviating suffering and promoting improvement in their quality of life... The recommended minimum package of care includes: treating episodes of ADLA/acute attacks among people with lymphoedema or elephantiasis, preventing both the debilitating and painful episodes of ADLA or acute attacks and the progression of lymphoedema or elephantiasis, enhancing access to hydrocele surgery, and providing antifilarial medicines through MDA or individual treatment to destroy any remaining worms and microfilariae... Intensive research efforts are focused on development and validation of new surveillance tools and strategies (such as the use of antibody assays to reflect exposure to infective larvae and xenomonitoring to confirm absence of parasites in the vectors), both to document the interruption of transmission of LF and to harmonize the process for verifying the elimination of LF with WHO verification processes for other diseases.

No MeSH data available.


Related in: MedlinePlus